4 September 2017
Juno Pharmaceuticals is the newest member of the Generic and Biosimilar Medicines Association (GBMA), the peak industry body representing companies that manufacture, supply and export generic and biosimilar medicines.
Following the signing of its first Strategic Agreement with the Australian Government in 2015, GBMA’s strong leadership and advocacy resulted in an extension to that Agreement through a landmark compact in May 2017.
“The extension of our Strategic Agreement with the Australian Government cements GBMA as a key stakeholder within the pharmaceutical sector. We provide a united voice of representation for our members and are proud to work collaboratively with government on issues regarding generic and biosimilar medicines,” said GBMA Chair, Allan Tillack.
“The addition of Juno to the GBMA membership recognises the strength and leadership of GBMA. I welcome Juno as our newest member and look forward to again working with former GBMA Chair, Mark Crotty,” he said.
Juno CEO and Managing Director Mark Crotty said: “Following Juno’s launch in 2013, we have established a base in Melbourne and a presence across Australia and New Zealand. Joining GBMA is part of Juno’s plan for growth and enables us to engage on policy development issues such as medicines shortages, sustaining generic prices and the evolution of the biosimilars sector.”